PMID- 24471974 OWN - NLM STAT- MEDLINE DCOM- 20141110 LR - 20171116 IS - 1440-1681 (Electronic) IS - 0305-1870 (Linking) VI - 41 IP - 3 DP - 2014 Mar TI - Aerobic interval training protects against myocardial infarction-induced oxidative injury by enhancing antioxidase system and mitochondrial biosynthesis. PG - 192-201 LID - 10.1111/1440-1681.12211 [doi] AB - 1. Aerobic interval training (AIT) exerts beneficial effects on cardiovascular disease. However, its cardioprotective mechanisms are not fully understood. The aim of the present study was to evaluate AIT-mediated anti-oxidation by focusing on anti-oxidase and mitochondrial biogenesis in rats after myocardial infarction (MI). 2. Sprague-Dawley rats were divided into three groups: (i) a sham-operated control (CON); (ii) an MI group; and (iii) an MI + AIT group. Myocardial microstructure and function, markers of oxidative stress, mitochondrial anti-oxidase, Phase II enzymes and mitochondrial biogenesis were assessed. In addition, levels of nuclear factor-erythroid 2-related factor (Nrf2) and phosphorylated (p-) AMP-activated protein kinase (AMPK) were determined. The anti-oxidative gene sirtuin 3 (SIRT3) and the prosurvival phosphatidylinositol-3 kinase (PI3-K)-protein kinase B (Akt) signalling cascade were also evaluated. 3. Compared with CON, there was noticeable microstructure injury, cardiac dysfunction and oxidative damage in rats after MI. In addition, decreased mitochondrial anti-oxidase content, Phase II enzyme (except heme oxygenase-1) expression and mitochondrial biogenesis were observed in the post-MI rats as well as reduced protein levels of the regulators Nrf2 and p-AMPK and suppression of SIRT3 levels and PI3-K/Akt signalling. These detrimental modifications were considerably ameliorated by AIT, as evidenced by increases in anti-oxidase, mitochondrial biogenesis, Nrf2 and AMPK phosphorylation, as well as SIRT3 upregulation and PI3-K/Akt signalling activation. Moreover, PI3-K inhibitor-LY294002 (20 mg/kg) treatment partly attenuated AIT-elicited increases in Nrf2 levels and AMPK phosphorylation. 4. Based on these results, we conclude that AIT effectively alleviates MI-induced oxidative injury, which may be closely correlated with activation of the anti-oxidase system and mitochondrial biosynthesis. Increased SIRT3 expression and activation of PI3-K/Akt signalling may play key roles in AIT-mediated anti-oxidation. These results open up new avenues for exercise intervention therapies for MI patients. CI - (c) 2014 Wiley Publishing Asia Pty Ltd. FAU - Jiang, Hong-Ke AU - Jiang HK AD - Department of Pharmacology, College of Medicine, Xi'an Jiaotong University, Xi'an, China; Department of Physical Education, Nan Yang Institute of Technology, Nan Yang, China. FAU - Miao, Yi AU - Miao Y FAU - Wang, You-Hua AU - Wang YH FAU - Zhao, Mei AU - Zhao M FAU - Feng, Zhi-Hui AU - Feng ZH FAU - Yu, Xiao-Jiang AU - Yu XJ FAU - Liu, Jian-Kang AU - Liu JK FAU - Zang, Wei-Jin AU - Zang WJ LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Australia TA - Clin Exp Pharmacol Physiol JT - Clinical and experimental pharmacology & physiology JID - 0425076 RN - 0 (Antioxidants) RN - 0 (NF-E2-Related Factor 2) RN - EC 2.7.1.137 (Phosphatidylinositol 3-Kinase) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.11.31 (AMP-Activated Protein Kinases) RN - EC 3.5.1.- (Sirtuin 3) SB - IM MH - AMP-Activated Protein Kinases/metabolism MH - Animals MH - Antioxidants/*metabolism MH - Male MH - Mitochondria/*metabolism/physiology MH - Mitochondrial Turnover/*physiology MH - Myocardial Infarction/metabolism/*physiopathology MH - NF-E2-Related Factor 2/metabolism MH - Oxidation-Reduction MH - Oxidative Stress/*physiology MH - Phosphatidylinositol 3-Kinase/metabolism MH - Physical Conditioning, Animal/*physiology MH - Proto-Oncogene Proteins c-akt/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Sirtuin 3/metabolism OTO - NOTNLM OT - aerobic interval training OT - anti-oxidase OT - mitochondrial biogenesis OT - myocardial infarction OT - phosphatidylinositol 3-kinase/Akt signalling OT - sirtuin 3 EDAT- 2014/01/30 06:00 MHDA- 2014/11/11 06:00 CRDT- 2014/01/30 06:00 PHST- 2013/08/01 00:00 [received] PHST- 2014/01/02 00:00 [revised] PHST- 2014/01/03 00:00 [accepted] PHST- 2014/01/30 06:00 [entrez] PHST- 2014/01/30 06:00 [pubmed] PHST- 2014/11/11 06:00 [medline] AID - 10.1111/1440-1681.12211 [doi] PST - ppublish SO - Clin Exp Pharmacol Physiol. 2014 Mar;41(3):192-201. doi: 10.1111/1440-1681.12211.